Literature DB >> 2650773

The presentation, management and prevention of crisis in sickle cell disease in Africa.

A F Fleming1.   

Abstract

About 120,000 infants are born each year with sickle cell disease (SCD) in Africa. The majority have Hb SS, but Hb SC and Hb S/beta+ thalassaemia are common in west Africa. The development of Plasmodium falciparum and P. malariae is partially inhibited in the Hb SS red cells, but malaria precipitates both haemolytic and infarctive crises, and is the commonest and most important cause of morbidity and mortality. The pneumococcus is likely to be the second major infectious cause of sickness and death. In one rural community, there were less than 2% of the expected number of subjects with SCD surviving beyond 5 years of age. Genetic factors improving prognosis include (1) the Senegal beta chain haplotype, which is linked to a high level of Hb F, and (2) alpha+ thalassaemia. Of environmental factors improving prognosis, the family is of first importance. The commonest age of presentation is 1-3 years. Children present with anaemic crises (malaria, splenic sequestration, folate deficiency, and possibly aplastic), infarctive crises (hand-foot syndrome, bone-pain, pulmonary and abdominal) or acute infections (malaria, pneumonia, septicaemia, meningitis, osteomyelitis). Tragically, many patients in central Africa have been infected by the human immunodeficiency virus (HIV) through blood transfusions; they present with generalised lymphadenopathy and other features of the acquired immunodeficiency syndrome (AIDS). The principles of management are (1) to ensure freedom from malaria, (2) to continue folic acid supplements, (3) to give blood transfusions only when anaemia endangers life, (4) to control pain, (5) to restore hydration, and (6) to prescribe broad spectrum antibiotics in large dosage and without delay, but only when there are definite indications, such as fever (greater than 39 degrees C), acute pulmonary disease, meningitis, and acute osteomyelitis. The advent of HIV and AIDS makes the control of SCD of even greater importance. Principles of control are (1) early diagnosis through appropriate laboratory techniques and selective screening, (2) education of parents, patients, health professionals and public, and (3) the maintenance of health at sickle cell clinics; measures must include antimalarial prophylaxis. SCD programmes should be integrated with primary health care and AIDS control programmes.

Entities:  

Mesh:

Year:  1989        PMID: 2650773     DOI: 10.1016/0268-960x(89)90022-2

Source DB:  PubMed          Journal:  Blood Rev        ISSN: 0268-960X            Impact factor:   8.250


  39 in total

1.  High mortality from Plasmodium falciparum malaria in children living with sickle cell anemia on the coast of Kenya.

Authors:  Charlotte F McAuley; Clare Webb; Julie Makani; Alexander Macharia; Sophie Uyoga; Daniel H Opi; Carolyne Ndila; Antony Ngatia; John Anthony G Scott; Kevin Marsh; Thomas N Williams
Journal:  Blood       Date:  2010-06-08       Impact factor: 22.113

Review 2.  Malaria chemoprophylaxis in sickle cell disease.

Authors:  O Oniyangi; A A A Omari
Journal:  Cochrane Database Syst Rev       Date:  2006-10-18

3.  Nonhematopoietic Nrf2 dominantly impedes adult progression of sickle cell anemia in mice.

Authors:  Samit Ghosh; Chibueze A Ihunnah; Rimi Hazra; Aisha L Walker; Jason M Hansen; David R Archer; Amma T Owusu-Ansah; Solomon F Ofori-Acquah
Journal:  JCI Insight       Date:  2016-04-07

Review 4.  Sickle cell disease in Africa: burden and research priorities.

Authors:  J Makani; T N Williams; K Marsh
Journal:  Ann Trop Med Parasitol       Date:  2007-01

Review 5.  Antibiotics for treating community-acquired pneumonia in people with sickle cell disease.

Authors:  Arturo J Martí-Carvajal; Lucieni O Conterno
Journal:  Cochrane Database Syst Rev       Date:  2016-11-14

6.  Malaria in patients with sickle cell anemia: burden, risk factors, and outcome at the outpatient clinic and during hospitalization.

Authors:  Julie Makani; Albert N Komba; Sharon E Cox; Julie Oruo; Khadija Mwamtemi; Jesse Kitundu; Pius Magesa; Stella Rwezaula; Elineema Meda; Josephine Mgaya; Kisali Pallangyo; Emelda Okiro; David Muturi; Charles R Newton; Gregory Fegan; Kevin Marsh; Thomas N Williams
Journal:  Blood       Date:  2009-11-09       Impact factor: 22.113

7.  Malaria as a cause of morbidity and mortality in children with homozygous sickle cell disease on the coast of Kenya.

Authors:  Albert N Komba; Julie Makani; Manish Sadarangani; Tolu Ajala-Agbo; James A Berkley; Charles R J C Newton; Kevin Marsh; Thomas N Williams
Journal:  Clin Infect Dis       Date:  2009-07-15       Impact factor: 9.079

8.  Sickle cell disease in central India.

Authors:  Archana B Patel; Ambarish M Athavale
Journal:  Indian J Pediatr       Date:  2004-09       Impact factor: 1.967

9.  Falciparum malaria infection in a case of sickle cell trait; unbalancing the balanced polymorphism.

Authors:  Amar Amale; Sourya Acharya; Samarth Shukla; Sameeksha Dubey
Journal:  Indian J Hematol Blood Transfus       Date:  2012-05-03       Impact factor: 0.900

10.  An observational study of children with sickle cell disease in Kilifi, Kenya.

Authors:  Manish Sadarangani; Julie Makani; Albert N Komba; Tolu Ajala-Agbo; Charles R Newton; Kevin Marsh; Thomas N Williams
Journal:  Br J Haematol       Date:  2009-07-23       Impact factor: 6.998

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.